However, this report differs from that of Santegoets and colleagues (and most reports monitoring the effects of immunotherapy on regulatory cell populations) in that rather than measuring circulating levels of Foxp3+ T cells, they instead measured the frequency of tumor-infiltrating cells that expressed Foxp3+ using pre-treatment biopsy samples from patients. This evidence concerns the gene FOXP3 and neoplasm.